UPC_CoA_744/2025

TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

AppealsMain AppealCourt of AppealGenericCase ClosedSettled at: Post-PI

Overview Decisions Documents Timeline

Parties

Claimants

Samsung Bioepis NL B.V.

Reps: Peter Meyer (Simmons & Simmons LLP)

Respondents

Alexion Pharmaceuticals, Inc.(AstraZeneca Group)

Reps: Elena Hennecke (Freshfields Bruckhaus Deringer)

Judges

Rian KaldenLegally Qualified Judge and Standing Judge

Patents

EP 3 167 888

CPC codes: A61P31/04, A61P25/18, A61P29/02, A61K39/395, A61K2039/505, A61P7/02, A61P25/26, A61P13/02, A61P15/10, A61P17/00, A61P7/00, A61P25/28…

Sector: Organic Chemistry

Outcome

Withdrawn

Filed: Aug 13, 2025

First decided: Feb 18, 2026

Language: English

Settled at: Post-PI

The Court of Appeal permitted Samsung Bioepis NL B.V.'s withdrawal of two applications for leave to appeal cost decisions (UPC_CoA_744/2025 and UPC_CoA_750/2025) in proceedings relating to provisional measures dismissed for lack of urgency before the Hamburg Local Division. Alexion consented to the withdrawal and waived any costs claim. The proceedings were declared closed with no costs order.

Open on UPC Registry